Sign In
Buy VRCA
$5.22
-0.0400 (-0.760%)
At Close: Jul 31, 2026
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
07:00am, Wednesday, 06'th Aug 2025
WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for ski
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
07:00am, Wednesday, 09'th Jul 2025
– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH ® dispensed applicator units in Q2 2025 – – Company reports receipt of $8 million milestone payme
– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule –
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
08:00am, Wednesday, 28'th May 2025
WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin
Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call
06:33pm, Tuesday, 13'th May 2025
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q1 2025 Corporate Update Conference Call May 13, 2025 4:30 PM ET Company Participants Kevin Gardner - Managing Director LifeSci Advisors Jayson Rieger - Pr
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
06:30pm, Tuesday, 13'th May 2025
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.38 per share a year ago.
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
04:05pm, Tuesday, 13'th May 2025
– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
08:00am, Wednesday, 07'th May 2025
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
08:00am, Wednesday, 30'th Apr 2025
WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for sk
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
04:05pm, Wednesday, 02'nd Apr 2025
WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for sk
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now
11:00am, Tuesday, 01'st Apr 2025
Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreem
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
08:00am, Monday, 31'st Mar 2025
WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for sk
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.
07:00am, Wednesday, 26'th Mar 2025
WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for sk
Verrica Pharmaceuticals, Inc. (VRCA) Q4 2024 Earnings Conference Call Transcript
08:30pm, Tuesday, 11'th Mar 2025
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants John Fraunces - Director, Corporate Communications, LifeSci Advisors, IR Ja
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates
06:25pm, Tuesday, 11'th Mar 2025
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.48 per share a year ago.
